We then investigated the association of CCR2 protein in prostate cancer patient tissue with time-to-event outcomes by performing univariable and multivariable analyses with 10-year endpoint data from the TROG 03.04 RADAR trial (Table 2). This evidence concerns the gene CCR2 and prostate carcinoma.